When evaluated with BMI as a continuous variable, apixaban was associated with a lower risk of stroke or SE, all-cause mortality, the composite endpoint, and
major bleeding across the range of BMI (per 1 kg/m2) compared with warfarin, with no significant interaction between the treatment effect and higher BMI
Probability of event, 1 year
0.08
0.06
0.04
0.02
0.00
BMI (kg/m2)
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
Stroke/Systemic Embolism
P value interaction = .69
Apixaban
95% CI
Warfarin
95% CI
Probability of event, 1 year
0.12
0.10
0.08
0.06
0.04
0.02
0.00
BMI (kg/m2)
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
All-Cause Mortality
P value interaction = .56
Apixaban
95% CI
Warfarin
95% CI
Probability of event, 1 year
0.15
0.10
0.05
0.00
BMI (kg/m2)
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
Stroke/SE, MI or All-Cause Mortality
P value interaction = .67
Apixaban
95% CI
Warfarin
95% CI
Probability of event, 1 year
0.08
0.06
0.04
0.02
0.00
BMI (kg/m2)
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
Major Bleeding
P value interaction = .08
Apixaban
95% CI
Warfarin
95% CI